MedTrace Logo

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

NCT02764268 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-03-11

No results posted yet for this study

Summary

Apatinib dose titration in Advanced or Metastatic Gastric Cancer

Conditions

Interventions

DRUG

Apatinib

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-02
Primary Completion
2018-12-10
Completion
2019-04-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02764268 on ClinicalTrials.gov